| Today's Big NewsApr 25, 2023 |
|
May 1 - 3, 2023 | Jersey City, NJ
Explore In-Depth Discussions Across 3 Tracks Dedicated to Medical Affairs Professionals. Last chance to register! Don’t miss out,register today.
|
|
| By Nick Paul Taylor Novartis has undertaken an old-fashioned decimation of its pipeline. The Swiss drugmaker has decided to dump or out-license 10% of its R&D projects to narrow its sights on five core therapeutic areas and focus investment on its most promising programs within those spaces. |
|
|
|
By Annalee Armstrong Long known as a neuroscience company, Biogen “could migrate” into immunology, CEO Christopher Viehbacher signaled Tuesday. |
By Annalee Armstrong With three launches to come this year, something has to give over at Biogen—and what's giving will be three programs in stroke, gene therapy and ophthalmology. |
By Max Bayer Arbutus Biopharma’s clinical trial aspirations are paused after the FDA slapped a clinical hold on an application to study a hepatitis B treatment. |
By Nick Paul Taylor Vedanta Biosciences has found investors willing to bankroll its phase 3 microbiome clinical trial. While a funding freeze recently forced Finch Therapeutics to fold its rival program, Vedanta has reeled in $106.5 million to challenge Seres Therapeutics’ near-approval SER-109 for an infectious disease opportunity. |
By Gabrielle Masson Novartis is doling out $40 million cash for exclusive licensing rights to 3B Pharmaceuticals’ cancer-targeting tech, wrapping up some loose ends for a radiotherapy picked up from Clovis Oncology at the end of last year. |
By James Waldron Slowing disease progression is the holy grail of many drug developers, but it can mess with a company’s timelines when encountered unexpectedly. |
By Max Bayer Mount Sinai is bolstering its regenerative medicine research with the establishment of a new institute. The Institute of Regenerative Medicine will have three related wings with the overarching goal of turning novel research into medicines. |
By James Waldron U.K. biotech investment got off to a “slow start” this year, with the amount raised in the first quarter dropping 39%, according to the latest report from an industry body. |
By Helen Floersh Preclinical success in primates could put a new gene therapy on the path to becoming the first-ever treatment for non-arteritic anterior ischemic optic neuropathy, along with many other aging diseases of the eye. |
By Zoey Becker After a partial clinical hold caused bluebird to miss its own first-quarter FDA filing goal, the company says its sickle cell disease gene therapy application is in. |
By Helen Floersh A new study illuminates a novel path to preventing chronic kidney transplant rejection in mice. The researchers hope their findings will lay the groundwork for a clinical trial. |
By Andrea Park The FDA is on a roll. Fresh off handing down an approval to Medtronic’s latest insulin pump, the agency has doled out a nod for yet another diabetes device, this time to Insulet. |
By Joseph Keenan Accel Research Sites Network, which operates clinical trial sites in the southern U.S., has expanded its operations with the addition of two sites in Florida. |
By Kevin Dunleavy Because of an enormous, front-loaded equity award deal in 2020, Regeneron's top two execs did not receive stock awards from the company in 2022. As a result, CEO Len Schleifer collected $7 million, while chief scientific officer George Yancopoulos pulled down $6.6 million, according to the company’s most recent SEC filing. |
By Dave Muoio An advocacy group representing big names like DaVita, Amazon and Ascension says the proposed legislation would be welcomed by beneficiaries and could help cut costs for the government. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we talk about how Pfizer became the first company in Big Pharma history with $100 billion in sales. We also dive into a J&J data leak, Eli Lilly's manufacturing spending plan and more of this week's top headlines. |
|
|---|
|
|
|
July 18-19, 2023 | Jersey City, NJ
Hear the latest industry trends from leaders in the field, and developed with input from our esteemed advisory board, to ensure you have a sound plan for your company, brands, and yourself. Save $500 when you Register Today!
|
|
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| Whitepaper The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
| Whitepaper We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
| Whitepaper How advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
